商品编号


F1111



品牌


UBPBio



公司


Ubiquitin-Proteasome Biotechnologies, LLC



公司分类


Inhibitors



Size

25 mg

商品信息

Ixazomib (MLN2238) (commercial name: Ninlaro?) is the first and only FDA-approved oral proteasome inhibitor for the treatment of multiple myeloma. It revers
IBL
y inhibits the chymotrypsin-like activity of proteasomes with IC50 of 3.4 nM in cell-free assays, also inhibits the caspase-like and trypsin-like activities of proteasome with IC50 of 31 and 3500 nM, respectively.


Additional Information






Product Name:

Ixazomib (MLN-2238)



Also Known As:

[(1R)-1-[[(2S,3R)-3-hydroxy-2-[(6-phenylpyridine-2-carbonyl)amino]butanoyl]amino]-3-methylbutyl]boronic acid



Catalog No.:

F1111



Size:

25 mg



CAS:

1072833-77-2



Formula:

C
14
H
19
BCl
2
N
2
O
4



Molecular Weight:

361.03 Da



Form:

Lyophilized powder



Quality Assurance:

>98% by HPLC and NMR



Source:

Synthetic



Storage:

Elig
IBL
e for room temperature shipping. Store at -80°C upon receiving



PDF Data Sheet:

Download PDF datasheet



Image(s):

N/A



Shipping Method:

Room temperature shipping



References:

N/A




Details

Ixazomib (MLN2238) (commercial name: Ninlaro?) is the first and only FDA-approved oral proteasome inhibitor for the treatment of multiple myeloma. It revers
IBL
y inhibits the chymotrypsin-like activity of proteasomes with IC50 of 3.4 nM in cell-free assays, also inhibits the caspase-like and trypsin-like activities of proteasome with IC50 of 31 and 3500 nM, respectively.

Solubility:

> 10 mg/ml in DMSO, < 1mg/ml="" in="" water,="" for="" in="" vivo="" use,="">30 mg/mL in 0.5% hydroxyethyl cellulose